Top Markets
Coin of the day
Fusion Antibodies plc Fusion Antibodies plc

Fusion Antibodies plc

FAB
Classifica tra le azioni #20442
Fusion Antibodies plc, a contract research organization, engages in the... Fusion Antibodies plc, a contract research organization, engages in the research, development, and manufacture of recombinant proteins and antibodies primarily for cancer and infectious diseases in the United Kingdom, the rest of Europe, North America, and internationally. It offers monoclonal antibody discovery and development, antibody sequencing, antibody engineering, antibody humanization and rational affinity maturation platform, recombinant protein expression, and stable cell line development and cGMP scale up services. The company serves pharmaceutical, biotech, and diagnostic companies. It has a collaboration partnership with Celonic AG. Fusion Antibodies plc was incorporated in 2000 and is headquartered in Belfast, the United Kingdom.
Prezzo delle azioni
$0.16328419
Capitalizzazione di mercato
$204.14K
Variazione (1 giorno)
4.35%
Variazione (1 anno)
102.45%
Paese
GB
Scambia Fusion Antibodies plc (FAB)

Categoria

Utile per Fusion Antibodies plc (FAB)
Utile nel Sep 2025 TTM: $-2.06M
Secondo gli ultimi rapporti finanziari di Fusion Antibodies plc, gli utili attuali della società sono $-2.06M. Nel 2024, la società ha registrato un utile di $-2.89M, un aumento rispetto a agli utili del 2023, che erano di $-3.53M. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Storico degli utili di Fusion Antibodies plc dal 2013 al 2026
Utile alla fine di ogni anno
Anno Utile Cambia
2026 (TTM) $-2.06M -10.23%
2025 $-2.30M -20.56%
2024 $-2.89M -18.12%
2023 $-3.53M 101.40%
2022 $-1.75M 0.58%
2021 $-1.74M 30.88%
2020 $-1.33M -31.84%
2019 $-1.95M 95.89%
2018 $-997.05K -731.20%
2017 $157.96K 304.33%
2016 $39.07K -126.49%
2015 $-147.46K -26.55%
2014 $-200.78K -72.11%
2013 $-719.78K 0.00%
Utile per aziende simili o concorrenti
Azienda Utile Differenza negli utili Il paese
$20.46B -992,770.77%
DK
$4.64B -225,408.48%
US
$5.23B -253,916.57%
US
$2.14B -103,830.35%
BE
$1.45B -70,512.80%
NL